Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
National Cancer Institute, NIH (R37 CA276928)
- License Information
-
More Information
Article History
Accepted: 24 June 2025
First Online: 24 September 2025
Declarations
:
: VRB reports participating in the Safety Monitoring Committee for Protagonist, serving as a member of the National Comprehensive Cancer Network Acute Myeloid Leukemia Panel, as an Associate Editor for the journal, Current Problems in Cancer, and as a contributor for BMJ Best Practice, and receiving consulting fees from Jazz, research funding (institutional) from Cynata Therapeutics, MEI Pharma, Actinium Pharmaceutical, Sanofi U.S. Services, Abbvie, Pfizer, Incyte, Jazz, and National Marrow Donor Program, and drug support (institutional) from Chimerix for a trial. There are no conflicts for other authors.
: All reported studies/experiments with human or animal subjects performed by the author have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).
